For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
VEGF can induce growth of pre-existing (angiogenesis) or de novo vessels (vasculogenesis), and is therefore key for embryonic development and vessel repair. VEGF is also hijacked by solid tumors to support their neoplastic growth.
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor 1 and 2 (PIGF-1 and PIGF-2, respectively)1,2. VEGF-A is the most potent inducer of blood vessel growth known to date, whereas VEGF-E is more specific for localized pathological processes of angiogenesis.
Family members are encoded by multiple exons that can can give rise different isoforms after alternative splicing, with consequence on solubility and receptor binding3. For example, VEGF-A exists in seven isoforms, while VEGF-B presents two isoforms.
VEGF family members transduce their signal intercellularly by binding to membrane-bound tyrosine kinase receptors: VEGF-A and B have a preference for VEGFR-1; VEGF-A, C, D and E can bind to VEGFR-2; VEGF-C and D to VEGFR-3 (expressed only in hematopoietic cells). The activation of VEGF receptors is considered one of the most critical events in angiogenesis3.
VEGF has activity in diverse cell types, such as muscle4 and neuronal cells5, however its main actions are on endothelial cells6. Family members play key roles in orchestrating the formation of new blood vessels, such as induction of gene expression, regulation of vascular permeability, and promotion of cell migration, proliferation and survival.
These are all induced by the binding of VEGF to VEGF-Rs, and the resulting activation of multiple downstream signaling pathways. These include: the Ras/MAPK pathway to regulate cell proliferation and gene expression; the FAK/paxillin pathway involved in the rearrangement of the cytoskeleton; the PI3K/AKT pathway regulating cell survival; the RhoA/ROCK pathway to form of new capillaries; the PLCγ pathway which controls vascular permeability6,7.
High levels of VEGF are observed during embryo development, where it cooperates with multiple endothelial growth factors to control the formation of new blood vessels1. As a consequence, disruption of VEGF pathways in mice increases embryonic lethality due to circulatory problems8.
Expression of VEGF decreases significantly after birth. However, localized levels can be up-regulated in tissues undergoing wound healing or fracture repair2. Recent studies have emphasized the role VEGF plays in pathological conditions involving the formation of new blood vessels, such as cancer, rheumatoid arthritis and age-related macular degeneration3,9,10.
Once the angiogenic switch is induced to promote the formation of new blood vessels, a complex and highly regulated sequence of events takes place. By activating multiple proteases, this pathway promotes the degradation of the basement membrane surrounding the existing vessel. This is followed by increased proliferation of endothelial cells, the formation of a lumen and a new basement membrane, and the fusion of newly formed vessels2.